Market Overview

Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting


- Oral presentation to include preclinical UCARTCS1A data in
Multiple Myeloma

- Poster presentation to focus on improved manufacturing for
allogeneic CAR T-cells

Regulatory News:

(NASDAQ:CLLS), a clinical-stage
biopharmaceutical company focused on developing immunotherapies based on
gene-edited allogeneic CAR T-cells (UCART), announces several
presentations at the upcoming 2019 American Society of Gene and Cell
Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2,
2019 in Washington, DC. Details on date and times of presentations can
be found below.

An oral presentation will demonstrate the potential of UCARTCS1A as a
treatment approach for patients with Multiple Myeloma. This presentation
follows the recent clearance of the UCARTCS1A IND by the FDA, IRB
approvals as well as clinical batch release.

A poster presentation will showcase Cellectis' allogeneic CAR T-cell
manufacturing expertise, focusing on a novel, straightforward and
efficient strategy to generate Universal CAR T-Cells. This exemplifies
how Cellectis' cutting-edge gene editing and cell engineering
capabilities can be leveraged to improve key features of our product

Furthermore, Julianne Smith, Ph.D., Vice President of Translational
Sciences, will be participating in a corporate review session at the
Gene Editing Workshop on Sunday, April 28, 2019 from 5:00 PM to 6:00 PM
EDT. Julianne will also be giving a presentation entitled "Allogeneic
Gene-Edited CAR T-Cells: From Preclinical to Clinical Proof of Concept"
on Tuesday, April 30 from 8:00 AM to 8:30 AM EDT during the Scientific
Symposium "Towards the Holy Grail of Cancer Gene Therapies: Universal
Cells, Targeted Vectors and Solid Tumor CART Efficacy".

Finally, Philippe Duchateau, Ph.D., Chief Scientific Officer of
Cellectis, will be participating in the Scientific Symposium "Innovation
in First Time in Human Study Clinical Studies" held on Monday, April 29
with a presentation titled "Universal Gene-Edited CAR T-Cell
Immunotherapy" from 9:30 AM to 10:00 AM EDT.

Oral presentation details:

  • UCARTCS1A: Allogeneic CAR T-Cells Targeting CS1 as Treatment for
    Multiple Myeloma

Roman Galetto1, Rohit Mathur2,
Mathilde Dusseaux1, Isabelle Chion-Sotinel1, Jing
Yang2, Diane Le Clerre1, Stephanie Filipe1,
Sattva Neelapu2, Julianne Smith3, Agnès Gouble1

1Cellectis SA, Paris, France
2MD Anderson
Cancer Center, Houston, TX, USA
3Cellectis Inc, New
York, NY, USA

Monday, April 29 – 3 :45 PM - 4 :00 PM EDT
CAR-T Cell
Therapies for Cancer Session
Room: International Ballroom West
Number: 139

Poster presentation details:

  • A Straightforward and Efficient Strategy to Generate Universal
    CAR T-Cells

Alexandre Juillerat1, Ming Yang1,
Diane Tkach1, Mohit Sachdeva1, Alex Boyne1,
Julien Valton1, Laurent Poirot2, Philippe Duchateau2

1Cellectis, Inc., 430E, 29th street, New York, NY 10016, USA
8 rue de la croix Jarry, 75013 Paris, France

Wednesday, May 1 – 5 :00 PM - 6 :00 PM EDT
Cell Therapies
III Session
Room: Columbia Hall
Abstract Number: 874

Abstracts are available on the ASGCT
. The two abstract presentations (oral and poster) to
be presented at the 2019 ASGCT Annual Meeting will be available on the Cellectis
after May 1, 2019.

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 19 years of
expertise in gene editing – built on its flagship TALEN®
technology and pioneering electroporation system PulseAgile – Cellectis
uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq (NASDAQ:CLLS) and on Euronext Growth (TICKER:ALCLS). To
find out more about us, visit our website:

Talking about gene editing? We do it. TALEN® is a registered
trademark owned by Cellectis.


This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risk factors that may affect company business
and financial performance is included in Cellectis' Annual Report on
Form 20-F and the financial report (including the management report) for
the year ended December 31, 2018 and subsequent filings Cellectis makes
with the Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the future.

View Comments and Join the Discussion!